Prions are the proteinaceous infectious agents responsible for the transmission of prion diseases. The main or sole component of prions is the misfolded prion protein (PrP Sc ), which is able to template the conversion of the host's natively folded form of the protein (PrP C ). The detailed mechanism of prion replication and the high-resolution structure of PrP Sc are unknown. The currently available information on PrP Sc structure comes mostly from low-resolution biophysical techniques, which have resulted in quite divergent models. Recent advances in the production of infectious prions, using very pure recombinant protein, offer new hope for PrP Sc structural studies. This review highlights the importance of, challenges for and recent progress toward elucidating the elusive structure of PrP Sc , arguably the major pending milestone to reach in understanding prions. r e V i e W npg
Transmissible spongiform encephalopathies (TSEs) are infectious disorders characterized by motor and cognitive impairments, extensive brain damage and neuronal dysfunction. After typically long incubation periods, individuals affected by TSEs deteriorate rapidly and progressively once the clinical symptoms arise, with lethal consequences in all cases. TSEs were first described in sheep exhibiting such abnormal behavior as erratic involuntary movements, ataxia and excessive scratching, and the disease was called scrapie 1 .
In humans, the most common TSE is Creutzfeldt-Jakob disease (CJD), which appears sporadically at a rate of one new case per million people per year 2 . Another human TSE is Kuru, first reported in 1954 among members of the Fore tribe in Papua New Guinea 2 , whose practice of cannibalism was thought to be a determinant for spreading the disease 3 . In fact, the infectious nature of TSEs quickly became evident, but early efforts to isolate the underlying agent were unsuccessful. The infectious agent was found to have unusual features, such as small size and resistance to procedures that inactivate nucleic acids 4 . More recently, an outbreak of TSE affecting cows (termed BSE) destined for human consumption raised worldwide concerns regarding potential transmission to humans 5 . This concern proved correct when a new variant form of CJD was identified and strongly linked to interspecies transmission from BSE 6, 7 .
The nature of the infectious entity associated with TSEs has been a matter of debate for years 8 . In 1967, John Griffith proposed that the scrapie infectious material was a self-replicating protein 9 . Decades later, experiments in animal models of TSE showed that infectivity was associated with a glycosylphosphatidylinositol (GPI)-anchored membrane protein termed prion protein (PrP) 10, 11 . It soon became clear that PrP exists in two forms: the normal protein present in healthy individuals, termed PrP C , for cellular PrP, and the protein found in infected animals, named PrP Sc after scrapie-associated PrP. There are no chemical differences between PrP C and PrP Sc , and their distinction is at the level of the structure and aggregation of the protein 12, 13 . Today the widely accepted prion hypothesis states that the infectious agent associated with TSE is a self-propagating protein in an aberrant or 'misfolded' conformation 14, 15 . Weissmann and co-workers achieved an important breakthrough for the prion hypothesis by showing that PrP knockout mice were completely resistant to scrapie 16 . Other supporting evidence came from experiments showing that transgenic mice expressing PrP mutations associated with fatal familial insomnia or modifications that rendered the loop at positions 166-175 more rigid develop spontaneous disease that is transmissible to wild-type animals 17, 18 . Perhaps the most important evidence came from the generation of infectious material in the test tube by in vitro conversion and replication of PrP C of both mammalian and recombinant origin [19] [20] [21] . One argument often used against the prion hypothesis is the existence of prion strains 8 , a phenomenon difficult to reconcile with an exclusively proteinaceous infectious agent. However, recent findings have shown that strain properties can be propagated in vitro, suggesting that all elements enciphering prion strains are encoded on the PrP Sc structure 22 .
Despite the clear involvement of PrP Sc in TSE pathogenesis, the mechanisms by which the misfolded protein causes brain damage and disease are for the most part unknown. The reasons for the disease's lethal outcome are the extensive synaptic damage, neuronal loss and widespread spongiform degeneration, but how PrP Sc is implicated in these processes is unclear. The current thinking on TSE, as well as other neurodegenerative diseases associated with protein misfolding and aggregation (Box 1), is that small oligomers of the misfolded protein are mainly responsible for neurotoxicity 23 . The relationship between PrP Sc polymer size and infectivity has been investigated using field-flow fractionation 24 and sedimentation velocity 25 , which showed that per mass of PrP monomer, the most infectious particles are small oligomers with 12-24 monomers.
The widespread involvement of protein misfolding in different pathologies (Box 1) indicates a more ubiquitous phenomenon underlying protein folding regulation at the cellular level. It is likely that other diseases not yet associated with prions may have similar roots, particularly given that the ability to form the highly structured supramolecular protein arrangements called amyloids is a trait encoded within the backbone of most, if not all, proteins 23 . In addition, the prion phenomenon seems to have non-pathogenic roles in certain organisms (Box 2).
Elucidating PrP Sc structure: importance and challenges
The structure of natively folded PrP C became available in 1996 (ref. 26 ), but the high-resolution three-dimensional structure of the abnormal form of PrP has remained elusive, along with mechanistic details of PrP Sc self-propagation. These are arguably the major remaining challenges in the prion field. Elucidating the structure of PrP Sc is essential to fully understand the mechanism of prion replication, just as the discovery of DNA structure enabled us to understand the process of genetic information transmission. Furthermore, the PrP Sc structure should clarify the molecular basis of the species barrier and could allow predicting which species or strains of PrP Sc can convert which PrP C sequences. Finally, the availability of the PrP Sc structure will provide a great incentive for the development of drugs to treat prion diseases.
The available evidence indicates that PrP Sc is a polymer composed of PrP monomers organized in an intermolecular β-sheet structure. Prion replication probably follows a seeding-nucleation model, in which PrP Sc acts as a seed to template the conversion of PrP C , incorporating it into the growing polymer [27] [28] [29] . The spontaneous (unseeded) formation of PrP Sc would be thermodynamically unfavorable, which may explain the low frequency of sporadic disease.
Solving the high-resolution structure of PrP Sc faces many, so far insurmountable, obstacles:
1. PrP Sc consists of a large collection of interconvertible polymers of different sizes in dynamic equilibrium in solution 24, 25 . Any particular prion strain is known to exist as a diverse population of PrP species with different buoyancy-associated densities 25 , which may correspond to different degrees of polymerization of an as-yet-unknown basic PrP Sc molecular unit. 2. PrP Sc aggregates typically have a high molecular weight 30 .
Although most infective PrP species seem to be rather small oligomers, these are still in the 400-to 600-kDa (ref. 24) range, which creates a substantial hurdle for classical biophysical analysis. 3. PrP Sc aggregates are mainly hydrophobic. Like other amyloidlike aggregates, prions are water-insoluble particles 31 , and under the conditions required for structural studies, PrP Sc forms non-crystalline aggregates that cannot be efficiently solubilized by any detergent tested 31 . Some degree of solubilization has been achieved with combinations of chemicals and heat treatments, but the resulting samples show a pronounced decrease in the infectivity titer, indicating that these procedures can change prion structure and its ability to self-propagate 32, 33 . More recent reports have described the isolation of partially detergent-soluble infectious PrP Sc oligomers that are markedly more protease sensitive than classical prions and may prove a suitable substrate for biophysical characterization 34 . 4. PrP Sc particles probably contain a mixture of PrP molecules with different degrees of glycosylation (di-, mono-and nonglycosylated) 35 . 5. Despite various protocols to purify PrP Sc , its sticky nature results in the capture of many contaminants inside the prion particle, including other proteins, lipids and nucleic acids 36 . 6. Current techniques to produce infectious prions in vitro have relatively low yield, which makes it difficult to generate sufficient material for biophysical studies.
Production of synthetic prions for structural studies
The difficulty in obtaining PrP Sc for structural studies by using brainderived material from diseased animals has led to attempts to produce synthetic PrP Sc with the biochemical, biological and infectious properties of bona fide prions. Such efforts included either chemically or physically altering the conformation of recombinant PrP produced in bacteria (recPrP) [37] [38] [39] [40] [41] . Whereas in vitro generation of amyloidlike aggregates by using recPrP is relatively straightforward, those aggregates typically lack infectivity 42 . The first landmark in synthetic prion generation was achieved by Prusiner and colleagues in 2004, who reported that in vitro-assembled recPrP amyloid fibrils could produce prion-like symptoms when injected into transgenic mice overexpressing a truncated form of PrP, after long incubation times 43 . However, the same fibrils lacked infectivity when injected into wild-type mice, raising justified concerns, given that transgenic animals overexpressing PrP have a well-known However, the analogies between fungal and mammalian prions are not straightforward. Fungal prions do not produce disease; moreover, they have structural features associated with highly organized, β-sheet-rich protein aggregates termed amyloids, whereas PrP Sc usually has a rather amorphous supramolecular organization. In both cases, the existence of different prion 'strains' arising from the same primary sequence has led to the hypothesis that a prion can adopt multiple conformations that can themselves selfpropagate through protein-protein interactions 107, 108 . [44] [45] [46] . Followup studies showed that disease can be transmitted to wild-type mice after multiple passaging in transgenic mice 47 . Moreover, aggregates prepared under various different conditions resulted in distinct strain properties upon serial passages in wild-type mice 47, 48 . Using a similar approach, Baskakov and colleagues reported that recPrP amyloid fibrils produced infectious prions after two successive passages in wild-type mice 49 . Although the animals did not show any symptoms upon direct injection of fibrils, a PrP Sc -like protease-resistant signal was detected by immunoblot analysis in several brains, after long incubation times.
BOX 2 Prions as genes
Although these results are encouraging, the very long incubation periods and the need for various in vivo passages before the agent showed the typical properties of prions point to differences between in vitro-produced recPrP aggregates and in vivo-generated PrP Sc . This is further supported by studies using X-ray fiber diffraction, hydrogen exchange and atomic force microscopy, showing that recPrP fibrils and PrP Sc appear to have substantially different cross-β-spine architectures [50] [51] [52] .
At least three scenarios can explain the differences between in vitro-generated recPrP aggregates and in vivo-generated PrP Sc (ref. 50): (i) recPrP aggregates may correspond to an 'immature' conformation that undergoes specific structural rearrangements in vivo toward a more infectious form that is equivalent to PrP Sc ; (ii) in vitro aggregation of recPrP results in a highly heterogeneous mixture of structures, of which only a minority has the folding and properties of infectious PrP Sc ; and (iii) some of the recPrP aggregates may inhibit replication of bona fide PrP Sc , resulting in the reduction of infectivity, increase of the incubation period and the inability to infect wild-type animals in the first passage. Regardless of which scenario is correct, at this point, it is clear that recPrP aggregates are not a suitable model to study the structure of infectious PrP Sc .
A more successful approach to generate PrP Sc in vitro has been to mimic prion replication in the test tube templated by brain-isolated PrP Sc . Initial attempts led to the cell-free conversion assay, developed by Caughey and colleagues 53 , in which radioactively labeled PrP C was incubated with a molar excess of PrP Sc , usually in the presence of a chaotrophic denaturing reagent. This resulted in small amounts of newly converted misfolded PrP that was resistant to proteolytic degradation, but its infectivity could not be tested, owing to the low efficiency of the system and the inability to distinguish newly formed PrP Sc from the original PrP Sc inoculum.
More recently, an efficient in vitro prion-replication system was developed, termed the protein misfolding cyclic amplification (PMCA) assay 54 . In this system, prions are replicated by mixing minute amounts of brain homogenates containing PrP Sc with healthy brain homogenates harboring PrP C . The replication of PrP Sc can be amplified exponentially, as PrP Sc polymers are fragmented by sonication, multiplying the number of seeds for conversion 54 . The newly converted PrP Sc has physicochemical properties identical to those of brain-derived PrP Sc and, more importantly, is highly infectious in wild-type animals 19 . PMCA allows faithful replication of prion strain properties 22 , including complex characteristics such as species barrier, strain adaptation and strain memory 55, 56 .
PMCA has become a powerful tool to culture prions in vitro, providing information on the nature of the infectious agent and the mechanism of prion replication, and serving as a highly sensitive prion-detection system. However, the use of brain homogenates limits its usefulness to provide structural information on the conversion process. Using highly purified PrP C from healthy brains as a substrate for PMCA, Supattapone and colleagues generated infectious prions with only the addition of synthetic polyanions 20 .
This was the first time prions were generated from pure components, but the need for polyanionic molecules and the presence of copurifying lipids raised questions about the involvement of non-PrP components during conversion. Although initial attempts to use recPrP as a substrate for PMCA were unsuccessful 57 , Wang and co-workers have reported the formation of prions from recPrP that were highly infectious to wild-type mice 21 . Notably, PrP Sc formation required not only recPrP but also synthetic lipids and mouse-isolated total RNA. The same authors reported that endogenous RNA can be replaced by synthetically produced RNA polynucleotide 58 . In other studies, recPrP prions were generated by PMCA, using only a combination of buffers and detergents 59 , but these showed a low-infectivity titer, reflected in highly variable attack rates (proportion of animals showing clinical symptoms) and long incubation times.
Altogether, these findings clearly indicate that non-protein components participate in prion replication, at least in vitro. The questions then are what specific functions do these non-PrP molecules have and which molecules fulfill these functions in vivo 15, 60, 61 . Cofactor molecules can influence PrP misfolding through at least two different mechanisms (Fig. 1) . In the first model, the cofactor may act as a catalytic molecule that binds both the normal and misfolded PrP forms and brings them together, lowering the activation energy for the conversion process (Fig. 1a) . Upon binding, the cofactor may also induce conformational changes in PrP C and/or PrP Sc that facilitate the interaction and conversion process. In the second model, the infectious PrP Sc conformation would be stabilized by the cofactor (Fig. 1b) . In biological terms, the main difference is whether the cofactor is a molecule provided by the host or a component of the infectious particle. In the latter case, the infectious agent would not be 'protein-only' but rather would consist of a complex between PrP Sc and the cofactor. This difference is not only important for clarifying the nature of the infectious agent, it is also crucial for the elucidation of the PrP Sc structure.
Although far from conclusive, the available evidence leans toward a scaffolding role for the cofactor (model 1). Negatively charged molecules (particularly nucleic acids, lipid particles and heparin sulfate proteoglycans) have long been proposed as PrP partners during conversion [62] [63] [64] , and aggregation of PrP in the presence of DNA or RNA is well known 62, 65, 66 . In addition, infectious prions form nuclease-and protease-resistant protein-nucleotide complexes in vitro. The scaffolding role to catalyze prion replication is also consistent with the observation that short-length nucleotides are highly inefficient in PMCA assays that are run with pure components 67 . PrP Sc -templated conversion of pure PrP C by PMCA in the presence of light-cleavable nucleotides generated infectious PrP that showed no differences in titer and strain properties when the nucleotides were hydrolyzed after conversion 68 , suggesting that polyanions act during conversion and do not need to be part of the infectious agent. Finally, though many molecules can be found associated with PrP Sc particles, no specific molecules are present in high quantity in the infectious material.
It is therefore likely that polyanionic molecules act as two-dimensional catalytic scaffolds that efficiently gather PrP C and PrP Sc , increasing the likelihood of conversion 63 . Still, the lack of high-resolution structural data makes it impossible to rule out the stabilizing role of a cofactor as an integral part of the infectious agent. In addition, cofactors could be involved in prion conversion through alternative pathways, as described elsewhere 15, 60 .
Probing the prion structure with low-resolution techniques
The unique properties of prion aggregates pose challenges for X-ray crystallization and NMR. Similar obstacles also exist for most amyloid npg r e V i e W systems, yet remarkable breakthroughs have been achieved with short peptides that form amyloid fibrils and are amenable to crystallization 69 . Those structures revealed unique peptide arrangements called steric zippers, that is, pairs of β-sheets that are stabilized by tight interdigitation 69, 70 . However, extrapolating these observations to full-length proteins is not trivial. The structure of the prion-forming domain of fungal prion Het-S has been solved 71 , revealing cross-β in-register amyloid-like structures. The relevance of these findings to mammalian prions is unclear, as infectious PrP Sc aggregates are typically not amyloid fibrils 42 .
As an alternative, several groups have used low-resolution biophysical and biochemical techniques to gather structural information on PrP Sc . Although these approaches do not provide information about tertiary contacts and the overall arrangement of PrP Sc , they can provide useful information for building structural models.
Initial efforts relied on classical spectroscopic techniques such as CD spectroscopy and FTIR spectroscopy, and revealed the predominantly β-sheet composition of PrP Sc isolated from diseased brains, in contrast to the mainly α-helical nature of normally folded PrP 13, 72, 73 . Indeed, characteristic IR spectral bands between 1,615 and 1,636 cm −1 associated with β-sheet structures are typically observed in prion samples. These findings were corroborated by FTIR for PrP Sc from many different strains and species [74] [75] [76] . These studies have also uncovered prion strain-associated differences in the secondary structure of PrPSc 75, 76 . However, the presence of complex glycans attached to PrP Sc , and its C-terminal GPI anchor, added considerable interference to the data. Recently, GPI-less transgenic mice able to replicate and produce infectious anchorless PrP Sc (ref. 77) were developed, and the PrP Sc obtained was also mostly non-glycosylated. FTIR analyses of this material showed no differences between wild-type and anchorless PrP Sc of a particular strain 52, 78 , indicating that glycans and GPI do not affect the overall prion structure.
Limited proteolysis has also provided structural information on PrP Sc . As early as the time of the first identification of PrP in the infectious material, it was clear that PrP Sc was substantially resistant to proteolysis 11 . Proteinase K treatment removes a fragment of about 12 kDa from the N terminus of PrP Sc (ref. 79) , resulting in a truncated form that retains infectious properties 80 and is often referred to as PrP27-30 because of the apparent size of the monomer in western blots. These observations suggest that the N-terminal region of PrP (up to around amino acid 90) is not essential for self-propagation. Experiments using transgenic mice expressing different PrP truncations confirmed that the minimal region required for sustaining PrP Sc in vivo propagation starts from residue ~90 all the way up to the C-terminal part of PrP 81 . Interestingly, distinct prion strains show different resistance to proteolytic degradation, and the cleavage site can also vary between distinct strains 82 . The latter has been used to argue that the folding and packing of PrP associated with distinct strains is different.
Antibody mapping studies have examined a panel of monoclonal antibodies with known epitopes in recognizing PrP Sc untreated or treated with denaturing agents, to investigate the accessibility of those sequences within the polymer. These studies showed that the region spanning residues ~90 to ~120 is not accessible to antibodies unless PrP Sc is completely denatured 83 , whereas segments located C-terminal to this region, such as the sequences 152-163 and 225-231, are accessible 84 .
The ultrastructural features of prions have been studied by transmission electron microscopy (TEM) 30, 85 and more recently by atomic force microscopy 86 . Brain-isolated PrP Sc molecules usually appear as amorphous aggregates of heterogeneous sizes. Upon exhaustive purification procedures, including prolonged protease treatment, the aggregates acquire more defined structures called prion rods. Rods are typically in the range of 10-to 100-nm long and 5-nm wide and are usually shorter than classical amyloid fibrils 47 . TEM analyses do not show appreciable differences between distinct strains. However, sedimentation velocity experiments have shown that sizedistribution patterns differ between distinct strains, and the size of the polymers tends to correlate with infectivity properties 25 . This agrees with the observation that strains containing higher proportions of oligomeric species self-propagate quickly and more efficiently in animal models 24 . Yet, prion strain isolates composed of larger aggregates were recently shown to propagate better in vivo 87 . The explanation was that larger aggregates may be more prone to fragmentation and may therefore spread prion seeds at higher rates. On the other hand, extensive sonication of PrP Sc aggregates right before intracerebral inoculation did not alter any of the strain properties of a particular isolate (263K), including the incubation period 88 . A plausible compromise interpretation is that prion strain differences lie within unique secondary and/or tertiary structural elements that give rise to strain-specific quaternary arrangements upon in vivo spreading. Therefore, the size distribution of a particular strain will be faithfully recovered upon injection even with low amounts of highly disrupted material. It is also important to consider that npg r e V i e W extensive manipulation of prions, including simple brain extraction in mild detergents, may well yield changes in the size distribution of aggregates. Finally, the highly dynamic interconversion of aggregates makes it difficult to evaluate the biological properties of isolated aggregates.
Although PrP Sc isolated from the brain of diseased animals does not form crystals amenable to X-ray crystallography, low-resolution diffraction patterns can be obtained by X-ray fiber diffraction 89 . This technique relies on the quasi-symmetrical scattering of fiberlike macromolecular aggregates upon X-ray bombardment. The data obtained are useful to study the packing of the core regions and the overall organization of the aggregates. This technique has been widely used to study the fiber-like organization of amyloids, and has revealed a motif called the cross-β-sheet, in which parallel β-sheets are stacked perpendicularly to the fiber axis. A similar motif was identified in PrP Sc . The fiber diffraction data of fibrils formed with protease-treated PrP Sc (PrP27-30) showed a sharp, albeit weak, meridional 4.72-Å cross-β-reflection, typical of amyloid aggregates, but the equatorial 10-Å reflection typical of amyloids was absent in PrP Sc , replaced by a weak and broad 8-Å signal 50 . These data suggest that PrP Sc has a structure with cross-β-packing similar to that in amyloid fibrils but with considerable differences.
Electron crystallography has also provided some clues about PrP Sc structural organization. This technique proves useful when very small crystals (usually with 2D spatial arrangements) are available, as electrons can interact more strongly with the protein crystal lattice than X-rays in thin samples, producing better beam diffraction. Using such an approach, combined with computational threading, Govaerts et al. produced one of the first structural models for PrP Sc , the β-helix structure 90 (discussed in the next section).
Alternative methods to obtain residue-level structural constraints can also yield information on the PrP Sc structure. EPR relies on the use of paramagnetic probes attached to certain amino acids in the protein that can report about site-specific structures as well as intra-and intermolecular distances 91 . EPR studies based on labeled recPrP subjected to in vitro misfolding showed evidence for a parallel, in-register β-sheet arrangement, similar to that of classical amyloids 92 , but the lack of infectivity of these samples raises questions about the extrapolation of these findings to the PrPSc structure. Hydrogen-deuterium exchange coupled to either MS (HX-MS) or NMR (HX-NMR) also provides residue-specific structural constraints by means of the degree of accessibility to water hydrogens within specific regions. Recently, the use of HX-MS was successful in showing that brain-isolated prions have a highly water-inaccessible core composed mainly of β-sheets and small loops spanning from residue ~90 to the C-terminal 52 . Moreover, several different strains had subtle differential exchanges in the region of residues 90 to 140, suggesting that specific conformational differences may be involved in prion strains 52 .
Structural models for PrP Sc
The information obtained from low-resolution biophysical techniques has been used to develop structural models for PrP Sc , with several proposed in the last decade. Here we describe and discuss some of these models.
The b-helix. This is one of the most popular models that was proposed based on EM data on 2D crystals 90 . The authors found that a left-handed β-helix would best fit the experimental data. A model was then constructed by threading the PrP sequence through a known β-helix motif (Fig. 2a) . In this model, a trimeric arrangement constitutes the basic symmetrical unit for PrP Sc , with the N-terminal residues of PrP27-30 (~90-175) forming left-handed β-helices that are horizontally stacked and include a long unstructured loop encompassing residues 145-163 (Fig. 2a) . Larger aggregates are formed by vertically stacking PrP trimers along the β-helical axis. In addition to a major refolding within the N-terminal region of PrP27-30, the model is characterized by only minor structural rearrangements in the C-terminal part of the protein, which retains most of its native secondary structure, except for the first small α-helix that switches to a loop (Fig. 2a) . Interestingly, the β-helical motif has been observed in other proteins that exhibit biochemical features reminiscent of PrP Sc , such as partial resistance to protease degradation and aggregation propensity 93, 94 . Remarkably, the fungal prion HET-s was shown to form a β-solenoid arrangement of β-sheets that is structurally similar to β-helices 71 .
The b-spiral. This model was proposed by Daggett and colleagues based on molecular dynamics simulations of PrP conformational fluctuations under amyloidogenic conditions (low pH), using the natively folded structure as the starting point 95 (Fig. 2b) . The model consists of a spiraling core of extended sheets, comprising three short β-strands (spanning residues 116-119, 129-132 and 160-164) and an isolated strand (residues 135-140) (Fig. 2b) . The advantage of this model is that the structural scaffold was not chosen arbitrarily; instead, the model is the result of a putative conversion pathway from the monomer to the misfolded oligomer. As with the β-helical model, formation of β-strands involves the natively unfolded N-terminal region of PrP27-30, whereas most of the C-terminal remains intact, preserving the three α-helices characteristic of PrP C . Fibrils are symmetrically arranged in a way that resembles spirallike amyloid organization (Fig. 2b) . This model satisfies many of the observations obtained by low-resolution techniques, except perhaps the proteolysis and the HX-MS data.
The extended in-register b-sheet. In this radically different model, proposed by Surewicz and colleagues, PrP Sc is represented as a stack of parallel β-sheets that form an in-register arrangement, allowing for indefinite growth of the fibrils (Fig. 2c) . This model is based on structural constraints obtained by HX-MS studies from recPrP fibrils 92 and with brain-derived PrP Sc (ref. 52). In the latter study, the authors used PrP27-30 isolated from prion-infected transgenic mice expressing mostly non-glycosylated PrP lacking the GPI anchor 77 to avoid interference from these post-translational modifications in the HX-MS studies. In this model, PrP Sc consists of β-strands and relatively short turns and/or loops, with no α-helices present (Fig. 2c) . Therefore, PrP conversion would involve refolding of the entire protein, and PrP Sc would not preserve any of the structural motifs of PrP C . The overall structure of the aggregates would resemble that of typical amyloid assemblies.
It is difficult to determine which of these three models is a closer representation of the PrP Sc structure, as they are all based on data from low-resolution biophysical experiments. Nevertheless, the fact that these models are so substantially different reflects how little we know about the structural details of PrP Sc .
A point of contention is the structural fate of the C-terminal domain, which is globular in PrP C , with well-defined and stable α-helices. In both the β-helical and the β-spiral models, the C-terminal domain retains most of its structure upon misfolding, whereas in the extended in-register β-sheet model, the entire protein refolds into a mainly β-sheet conformation. The latter model fits the proteolysis data better, as it is difficult to understand the high resistance to proteolytic degradation of the C-terminal part of PrP Sc if its structure is not substantially different from PrP C , in which this region is easily cleaved by proteases. Indeed, in both the β-helix and spiral models, the α-helical domains face the outside of the polymer, hence they should be at least partially accessible to proteases.
On the other hand, the extended in-register β-sheet model is in conflict with CD and FTIR studies indicating a substantial amount of α-helical structure in PrP Sc . Indeed, different groups have consistently reported that PrP Sc is 15-35% α-helical 13, 19, [72] [73] [74] [75] [76] . The majority of these experiments were conducted with FTIR, in which peaks at ~1,556-1,661 cm −1 were attributed to α-helices. However, this assignment is not always straightforward because other structures, including turns, loops and unordered segments, can also give rise to amide I bands in this frequency range 96 . Indeed, bands around 1,656-1,658 cm −1 have been observed in FTIR spectra of proteins that had no α-helices, according to X-ray crystallography or NMR spectroscopy data 96, 97 . Moreover, a report using FTIR to analyze both wild-type and GPI anchorless PrP Sc has cast doubt on the presence of α-helices 78 . Finally, the extended in-register β-sheet model has many similarities to the high-resolution structures of short peptides aggregated into amyloid fibrils and of yeast prions, suggesting that this is a plausible model for misfolded aggregates that have the ability to self-propagate. Nevertheless, these similarities represent a double-edged sword because, as discussed above, the infectious folding of PrP Sc seems to be different from that of classical amyloid fibrils.
Conclusions and perspectives
The ability of proteins to self-propagate specific conformations and associated biological functions continues to fascinate researchers. The once heretical hypothesis that a protein can act as an infectious agent to propagate disease is now widely accepted, and the prion principle is being extended to other degenerative diseases associated with the accumulation of misfolded proteins [98] [99] [100] [101] . However, several key questions about prion biology, including the mechanisms of toxicity, the molecular basis of in vivo prion propagation and the detailed PrP Sc structure, remain unanswered. Moreover, it is possible that new findings about the role of as-yet-unidentified cofactor molecules may undermine this already controversial hypothesis by demonstrating the participation of an essential non-protein component in PrP selfreplication and infectivity.
From the key unanswered questions in the prion field, determination of the high-resolution structure of PrP Sc will undoubtedly be a major step in understanding the mechanism by which proteins can propagate biological information. The structure of PrP Sc should also reveal the mysterious relationship between prion strains and PrP Sc conformation and enable the rational design of much-needed treatments for these devastating diseases.
